Skip to Main Content

Paper Details

HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma.
Clinical Cancer Research
13
2022
AKT, BRAF, BRAFV600E, BRAFV600E HGG models, BRAFV600E-mutant, BRAFV600E-mutant HGG, BRAFV600E-mutant HGG patient-derived xenograft models, BRAFV600E-mutant High-grade Glioma, BRAFV600E-mutant high, Bcl-2 family proteins, GSK3, HGG, HSP90, MAPK, MEK, Ser9, c-Raf, high-grade gliomas, mTOR, patient, refractory models
Author NameAffiliation
Hiroyuki ManoNational Cancer Center Research Institute
  • 1 - 1

Datasets

Release 1.2